Venous Thromboembolism in Pregnancy Study

NCT ID: NCT00856076

Last Updated: 2011-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate clinical, biochemical and genetic risk factors for venous thromboembolism in pregnancy and pregnancy related vascular complications, and the long-term outcome of such complications including implications for quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Venous thromboembolism (VTE) in pregnancy is a serious, but rare condition. There is no epidemiological data on this patient group from Norway, and there is generally little literature on the immediate and long-term outcome after such pregnancies. Approximately 50% of the women with VTE in pregnancy have known thrombophilia. These women also carry a considerably increased risk for intrauterine fetal death (IUFD). In this project we want to identify new thrombophilias as risk factors for VTE and IUFD in pregnancy.

Aims:

Using a case-control design we will investigate the following issues:

* Risk factors for VTE in pregnancy and IUFD
* Association between thrombophilia, VTE, and other vascular pregnancy complications including IUFD
* Association between thrombophilia and IUFD
* Long term effects of VTE in pregnancy and IUFD on future health including quality of life
* Association between "single nucleotide polymorphisms" (SNP) in genes coding for specific coagulation-, fibrinolysis-, inflammatory, and other relevant proteins and their phenotypic expression
* Association between relevant phenotypes of coagulation, fibrinolysis, inflammation, and other relevant pathways and their risk of disease
* Association between the frequency of specific SNPs that codes for coagulation-, fibrinolysis-, inflammatory, and other relevant proteins and risk for VTE

Materials and Methods:

* 300 women with a history of VTE in their pregnancy and 150 women with IUFD will be identified by the Norwegian patient registry (NPR) and the Medical Birth Registry (MFR). The medical records of these patients will be checked. The epidemiological data will be collected with the help of questionnaires that the patients will fill out and blood samples will be collected. Blood samples will be analyzed with the aim to check for known coagulation factors and thrombophilias as well as new gene polymorphisms.
* 600 control women, from the maternity wards at Ullevål/Aker University Hospitals in the same time period, matched for age and ethnicity, will also answer questionnaires and donate blood samples. The medical records for these women will be checked.

Ethical problems: This study raises no new ethical problems. The study is based on voluntary participation from the invited and informed consent for all analyzes of biological test material. The study design, data procedures and storing of biological material, will use methods that assure the patients privacy at all levels.

The participants are invited to fill out a questionnaire concerning information of thrombosis in pregnancy and take one simple blood test. Women with symptoms of post thrombotic syndrome (PTS) will be offered a clinical examination of their lower extremities to verify the condition. The data will be de-identified and the individuals will not be able to be identify by other than those that have concession to the patient register established for this study.

Blood tests will be stored in a biobank at Ullevål University Hospital (UUS) established for this study, and will only be used for research related problems that have to do with this study.

Some patients could have a psychological reaction of the illness they experienced many years ago. The project leader or co-workers from the Hematology Department/Research Laboratory will handle this problem. These patients will be offered additional information on thrombosis in pregnancy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism Intrauterine Fetal Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VTE case group 1/2

Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.

No interventions assigned to this group

VTE control group 1

All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.

No interventions assigned to this group

VTE control group 2

Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.

No interventions assigned to this group

VTE case group 3

Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.

No interventions assigned to this group

VTE control group 3

Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.

No interventions assigned to this group

IUFD group 1

Women who have experienced IUFD - data verified from medical records.

No interventions assigned to this group

IUFD group 2

Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.

No interventions assigned to this group

IUFD control group 1

All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.

No interventions assigned to this group

IUFD control group 2

Subjects from VTE control group 1/2 with validated data from medical records.

No interventions assigned to this group

IUFD control group 3

Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women with first-time objectively verified venous thromboembolism in pregnancy.
* women with history of intrauterine fetal death.

Exclusion Criteria

* recurrent venous thromboembolism in pregnancy.
* non-validated venous thromboembolism in pregnancy.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oslo University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Per Morten Sandset, MD, PhD

Role: STUDY_DIRECTOR

Oslo University Hospital Ullevål and University of Oslo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Oslo University Hospital Ullevaal (formerly Ullevaal University Hospital)

Oslo, , Norway

Site Status RECRUITING

Oslo University Hospital (formerly Ullevaal University Hospital)

Oslo, , Norway

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Per-Morten Sandset, MD; PhD

Role: CONTACT

+4722119247

References

Explore related publications, articles, or registry entries linked to this study.

Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skogstad M, Sandset PM. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study. Thromb Res. 2010 May;125(5):e222-7. doi: 10.1016/j.thromres.2009.12.006. Epub 2010 Jan 6.

Reference Type BACKGROUND
PMID: 20051285 (View on PubMed)

Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol. 2008 Feb;198(2):233.e1-7. doi: 10.1016/j.ajog.2007.08.041. Epub 2007 Nov 12.

Reference Type RESULT
PMID: 17997389 (View on PubMed)

Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008 Jun;6(6):905-12. doi: 10.1111/j.1538-7836.2008.02961.x. Epub 2008 Mar 21.

Reference Type RESULT
PMID: 18363820 (View on PubMed)

Gravensteen IK, Helgadottir LB, Jacobsen EM, Radestad I, Sandset PM, Ekeberg O. Women's experiences in relation to stillbirth and risk factors for long-term post-traumatic stress symptoms: a retrospective study. BMJ Open. 2013 Oct 22;3(10):e003323. doi: 10.1136/bmjopen-2013-003323.

Reference Type DERIVED
PMID: 24154514 (View on PubMed)

Gravensteen IK, Helgadottir LB, Jacobsen EM, Sandset PM, Ekeberg O. Long-term impact of intrauterine fetal death on quality of life and depression: a case-control study. BMC Pregnancy Childbirth. 2012 Jun 7;12:43. doi: 10.1186/1471-2393-12-43.

Reference Type DERIVED
PMID: 22676992 (View on PubMed)

Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost. 2010 Nov;8(11):2443-9. doi: 10.1111/j.1538-7836.2010.04038.x.

Reference Type DERIVED
PMID: 20735725 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VIP-study

Identifier Type: -

Identifier Source: org_study_id